Inotuzumab ozogamicin

Specification

• Cat#: THA-0034
• Product Name: Inotuzumab ozogamicin
• Description: Inotuzumab ozogamicin is an antibody-drug conjugate used to treat B-cell precursor acute lymphoblastic leukemia (ALL).
• Sequences: Not Available
• Molecular Weight: Not Available
• Introduction: Inotuzumab ozogamicin is an antibody-drug conjugate consisting of a humanized IgG4 kappa CD22-targeting monoclonal antibody covalently attached to calicheamicin derivative, N-acetyl-gamma-calicheamicin dimethylhydrazide. The antibody portion of the drug binds to CD22 receptors expressed on leukemic B cells and intracellularly releases N-acetyl-gamma-calicheamicin dimethylhydrazide, which produces cytotoxic effects. Inotuzumab ozogamicin was first approved by the European Commission in June 2017 for the treatment of relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). A month later, inotuzumab ozogamicin was also approved by the FDA.
• Purity: >99% by SDS-Page and HPLC analysis
• Formula: Not Available
• Appearance: Solid
• Endotoxin Level: < 0.001 EU/μg of the protein by the LAL method

Pharmaceutical Information

• Pharmacodynamics: Inotuzumab ozogamicin is an antineoplastic agent that works to deplete CD22-positive leukemic cells. In preclinical models, it arrested tumour growth and reduced the number of ALL cells. In clinical trials, inotuzumab ozogamicin was shown to prolong the QT interval.
• Targets: B-cell receptor CD22